The first quarter of 2025 has marked an important period for AB-BIOTICS, with three major launches across key global markets. These rollouts reflect our ongoing commitment to science-backed innovation and strategic partnerships in areas with high unmet needs.
Shape100™
Event: Vitafoods Europe, Barcelona – May 2025
Partner: Wonderlab (China)
At Vitafoods Europe, Wonderlab—one of China’s leading dietary supplement companies—introduced Shape100™, a microbiota-targeted weight management solution developed using AB-LIFE. The product generated strong interest, supported by a live presentation from Wonderlab’s marketing team and positive feedback from a key opinion leader who had tested the formula.
Positioned for cardiometabolic and metabolic health, the formulation is supported by robust clinical evidence showing its ability to reduce both endogenous and dietary cholesterol, improve insulin sensitivity, and support fat metabolism through bile salt hydrolase (BSH) activity.
Kaleidon AB-Kolicare
Event: AEP Congress, Valencia – June 2025
Partner: Menarini Spain
During the Spanish Congress of Pediatrics, Menarini presented a new addition to their Kaleidon range, focused on the management of infantile colic. The launch featured clinical materials, sampling, and an expert-led symposium with approximately 200 healthcare professionals in attendance.
The formulation has demonstrated fast-acting relief from FGID symptoms, with clinical benefits observed as early as day 7. Its safety, strong responder rate, and effectiveness across feeding types make it a trusted option in pediatric care.
Lactoflora Menopausia
Event: Madrid – June 2025
Partner: STADA Spain
STADA introduced their latest innovation in women’s health during a dedicated event in collaboration with the Spanish Menopause Society (AEEM). The session combined the presentation of national epidemiological data with expert talks on the estrobolome and hormonal balance during menopause.
This formulation is the first probiotic clinically shown to support estrogen regulation via microbial β-glucuronidase activity, offering a natural alternative to hormone replacement therapy. Its benefits span both physical and emotional symptoms throughout all stages of menopause.
Looking ahead
From women’s health to pediatric care and cardiometabolic wellness, AB-BIOTICS continues to expand its global footprint through evidence-based innovation. These recent launches reflect not only scientific strength but also the trust of our commercial partners in delivering value to healthcare professionals and consumers alike.
To find out more about our precision probiotics for a range of health areas, contact us today at hello@ab-biotics.com.